In a few clinical studies, DAXX or DAXX/ATRX expression loss was correlated with chromosomal instability and predicted relapse in patients with low-stage cancer (i.e., stage I–III with no distant metastasis) with DNA hypomethylation regulation [11,49]. The gene discussed is ATRX; the disease is cancer.